Clinical Significance of NAT2 Genetic Variations in Type II Diabetes Mellitus and Lipid Regulation

Overview

Journal Pharmgenomics Pers Med

Publisher Dove Medical Press

Date 2023 Sep 19

PMID 37724295

Authors

Yazun Jarrar

Sara Abudahab

Ghasaq Abdul-Wahab

Dana Zaiter

Abdalla Madani

Sara J Abaalkhail

Dina Abulebdah

Hussam Alhawari

Rami Musleh

Su-Jun Lee

Affiliations

Soon will be listed here.

Abstract

Background: N-acetyltransferase 2 (NAT2) enzyme is a Phase II drug-metabolizing enzyme that metabolizes different compounds. Genetic variations in can influence the enzyme's activity and potentially lead to the development of certain diseases.

Aim: This study aimed to investigate the association of variants with the risk of Type II diabetes mellitus (T2DM) and the lipid profile among Jordanian patients.

Methods: We sequenced the whole protein-coding region in using Sanger's method among a sample of 45 Jordanian T2DM patients and 50 control subjects. Moreover, we analyzed the lipid profiles of the patients and examined any potential associations with variants.

Results: This study revealed that the heterozygous genotype is significantly ( = 0.03) more common among T2DM (44%) than non-T2DM subjects (23.5%). Furthermore, the frequency of homozygous genotype was found to be significantly higher ( = 0.03) among T2DM patients (26.7%) compared to that of non-T2DM subjects (11%). The heterozygous genotype was exclusively observed in T2DM patients (11.1%) and absent in the control non-T2DM group. Moreover, among T2DM patients, those with a homozygous T/T genotype exhibited significantly higher levels of triglycerides (381.50 ± 9.19 ng/dL) with a value of 0.01 compared to those with heterozygous C/T (136.23 ± 51.12 ng/dL) or wild-type C/C (193.65 ± 109.89 ng/dL) genotypes. T2DM patients with homozygous G/G genotype had a significantly ( = 0.04) higher triglyceride levels (275.67 ± 183.42 ng/dL) than the heterozygous (140.02 ± 49.53 ng/dL) and the wild (193.65 ± 109.89 ng/dL).

Conclusion: The finding in this study suggests that the gene is a potential biomarker for the development of T2DM and changes in triglyceride levels among Jordanians. However, it is important to note that our sample size was limited; therefore, further clinical studies with a larger cohort are necessary to validate these findings.

References

Srivastava D, Aggarwal K, Singh G . Is Gene Polymorphism Associated with Vitiligo?. Indian J Dermatol. 2020; 65(3):173-177. PMC: 7292445. DOI: 10.4103/ijd.IJD_388_18. View

Zhu K, Xu A, Xia W, Li P, Zhang B, Jiang H . Association Between NAT2 Polymorphism and Lung Cancer Risk: A Systematic Review and Meta-Analysis. Front Oncol. 2021; 11:567762. PMC: 7991837. DOI: 10.3389/fonc.2021.567762. View

Khamees M, Jarrar Y, Al-Qirim T, Mahmoud I, Hatmal M, Alshaer W . No impact of soluble epoxide hydrolase rs4149243, rs2234914 and rs751142 genetic variants on the development of type II diabetes and its hypertensive complication among Jordanian patients. Int J Clin Pract. 2021; 75(5):e14036. DOI: 10.1111/ijcp.14036. View

Silva T, Felipe A, de Lima J, Oshima C, Forones N . N-Acetyltransferase 2 genetic polymorphisms and risk of colorectal cancer. World J Gastroenterol. 2011; 17(6):760-5. PMC: 3042654. DOI: 10.3748/wjg.v17.i6.760. View

Jarrar Y, Al-Essa L, Kilani A, Hasan M, Al-Qerem W . Alterations in the gene expression of drug and arachidonic acid-metabolizing Cyp450 in the livers of controlled and uncontrolled insulin-dependent diabetic mice. Diabetes Metab Syndr Obes. 2018; 11:483-492. PMC: 6162993. DOI: 10.2147/DMSO.S172664. View

Cui D, Wang Z, Zhao E, Ma J, Lu W . NAT2 polymorphism and lung cancer risk: a meta-analysis. Lung Cancer. 2011; 73(2):153-7. DOI: 10.1016/j.lungcan.2010.12.012. View

. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010; 33 Suppl 1:S62-9. PMC: 2797383. DOI: 10.2337/dc10-S062. View

Knowles J, Xie W, Zhang Z, Chennamsetty I, Assimes T, Paananen J . Identification and validation of N-acetyltransferase 2 as an insulin sensitivity gene. J Clin Invest. 2016; 126(1):403. PMC: 4701558. DOI: 10.1172/JCI85921. View

Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe K . Pathophysiology of Type 2 Diabetes Mellitus. Int J Mol Sci. 2020; 21(17). PMC: 7503727. DOI: 10.3390/ijms21176275. View

10.

Al-Shaqha W, Alkharfy K, Al-Daghri N, Mohammed A . N-acetyltransferase 1 and 2 polymorphisms and risk of diabetes mellitus type 2 in a Saudi population. Ann Saudi Med. 2015; 35(3):214-21. PMC: 6074463. DOI: 10.5144/0256-4947.2015.214. View

11.

Irshaid Y, Abujbara M, Ajlouni K, El-Khateeb M, Jarrar Y . N-acetyltransferase-2 genotypes among Jordanian patients with diabetes mellitus. Int J Clin Pharmacol Ther. 2013; 51(7):593-9. DOI: 10.5414/CP201883. View

12.

Ohno M, Yamaguchi I, Yamamoto I, Fukuda T, Yokota S, Maekura R . Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis. 2000; 4(3):256-61. View

13.

Crossley B, Bai J, Glaser A, Maes R, Porter E, Killian M . Guidelines for Sanger sequencing and molecular assay monitoring. J Vet Diagn Invest. 2020; 32(6):767-775. PMC: 7649556. DOI: 10.1177/1040638720905833. View

14.

Luca F, Bubba G, Basile M, Brdicka R, Michalodimitrakis E, Rickards O . Multiple advantageous amino acid variants in the NAT2 gene in human populations. PLoS One. 2008; 3(9):e3136. PMC: 2527519. DOI: 10.1371/journal.pone.0003136. View

15.

McDonagh E, Boukouvala S, Aklillu E, Hein D, Altman R, Klein T . PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2. Pharmacogenet Genomics. 2014; 24(8):409-25. PMC: 4109976. DOI: 10.1097/FPC.0000000000000062. View

16.

Yan D, Jiao Y, Yan H, Liu T, Yan H, Yuan J . Endocrine-disrupting chemicals and the risk of gestational diabetes mellitus: a systematic review and meta-analysis. Environ Health. 2022; 21(1):53. PMC: 9109392. DOI: 10.1186/s12940-022-00858-8. View

17.

Yalin S, Hatungil R, Tamer L, Ates N, Dogruer N, Yildirim H . N-acetyltransferase 2 polymorphism in patients with diabetes mellitus. Cell Biochem Funct. 2006; 25(4):407-11. DOI: 10.1002/cbf.1314. View

18.

Lucena-Aguilar G, Sanchez-Lopez A, Barberan-Aceituno C, Carrillo-Avila J, Lopez-Guerrero J, Aguilar-Quesada R . DNA Source Selection for Downstream Applications Based on DNA Quality Indicators Analysis. Biopreserv Biobank. 2016; 14(4):264-70. PMC: 4991598. DOI: 10.1089/bio.2015.0064. View

19.

Scarpelli D, Cardellini M, Andreozzi F, Laratta E, Letizia Hribal M, Marini M . Variants of the interleukin-10 promoter gene are associated with obesity and insulin resistance but not type 2 diabetes in caucasian italian subjects. Diabetes. 2006; 55(5):1529-33. DOI: 10.2337/db06-0047. View

20.

Hein D, Doll M, Fretland A, Leff M, Webb S, Xiao G . Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev. 2000; 9(1):29-42. View